

O I P E  
SEP 24 2003  
PATENT & TRADEMARK OFFICE

1614  
PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/603,441
Filing Date	June 25, 2003
First Named Inventor	Daniel P. Becker, et al.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	01136/1/US

Total Number of Pages in This Submission

## ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Response

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ 2nd Supplemental Information  
Disclosure Statement

☐ Certified Copy of Priority  
Document(s)

☐ Response to Missing Parts/  
Incomplete Application

☐ Response to Missing  
Parts under 37 CFR  
1.52 or 1.53

☐ Assignment Papers  
(for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a  
Provisional Application

☐ Power of Attorney, Revocation  
Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) \_\_\_\_\_

☐ After Allowance Communication to  
Group

☐ Appeal Communication to Board of  
Appeals and Interferences

☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s)  
(please identify below):

FORM HDP-1449

36 References

Return Receipt Postcard

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm  
or  
Individual name

David M. Gryte, PTO Reg. No. 41,809  
Harness, Dickey & Pierce, P.L.C.

Signature

Date

September 24, 2003

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on this date: September 24, 2003

Typed or printed name

Peggy Marie Leslie

Signature

Peggy Marie Leslie

Date

September 24, 2003

EV 311408213 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 29 2003

TECH CENTER 1600/2900

Application of: Daniel P. Becker, et al.  
Serial No: 10/603,441  
Filed: June 25, 2003  
For: Hydroxamic Acid and Amide Compounds and Their Use as Protease Inhibitors  
Confirmation No: 4396  
Art Unit: 1614  
Examiner: TBA  
Attorney Ref: 01136/1/US  
HDP Ref: 6794-000057/US

September 24, 2003

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed supplemental Form PTO-1449 and copies of all documents listed on that form.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration and that the Examiner cite each document of record in the prosecution history of the present application by initialing Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a listed document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.5, but by listing such documents Applicants are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b) and, in the course of such

Appl. No. 10/603,441  
Information Disclosure Statement  
September 24, 2003

search, will review for relevance every document listed on the attached form even if not initialed.


Applicants make no representation as to the accuracy of any translation provided with this Information Disclosure Statement.

Applicants request early and favorable consideration.

\* \* \* \* \*

Applicants believe that they do not owe any fee in connection with this Information Disclosure Statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.


Respectfully submitted,




David M. Gryte, PTO Reg. No. 41,809  
Harness, Dickey & Pierce  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (tel)  
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **September 24, 2003** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



DMG/PML



RECEIVED  
SEP 29 2003  
TECH CENTER 1000/2000

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET NO.

01136/1/US

SERIAL NO.

10/603,441

APPLICANTS

Daniel P. Becker, et al.

FILING DATE

June 25, 2003

GROUP

1614

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

**FOREIGN PATENT DOCUMENTS**


Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
32.		WO 99/42436	8/26/99	PCT	C07C 239/14		
33.		WO 99/25687	5/27/99	PCT	C07D 211/66		
34.		WO 99/09000	2/25/99	PCT	C07C 235/00		
35.		WO 98/38163	9/3/98	PCT	C07C 323/60		
36.		WO 98/37877	9/3/98	PCT	A61K 31/16		
37.		WO 97/24117	7/10/97	PCT	A61K 31/19		
38.		WO 97/20824	6/12/97	PCT	C07D 241/04		
39.		WO 96/11209	4/18/96	PCT	C07K 5/06		
40.		WO 96/06074	2/29/96	PCT	C07C 259/06		
41.		WO 95/29892	11/9/95	PCT	C07D 207/327		
42.		WO 95/13289	5/18/95	PCT	C07K 5/062		
43.		WO 95/09841	4/13/95	PCT	C07C 323/60		
44.		WO 94/24140	10/27/94	PCT	C07H 13/04		
45.		WO 94/02466	2/3/94	PCT	C07D 221/14		
46.		WO 93/20047	10/14/93	PCT	C07C 317/44		

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 311408213 US

**RECEIVED**

SEP 29 2003

TECH CENTER 1600/2300

FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET NO.

01136/1/US

SERIAL NO.

10/603,441

APPLICANT

Daniel P. Becker, et al.

FILING DATE

June 25, 2003

GROUP

1614

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation	
						Yes	No
47.		WO 90/05719	5/31/90	PCT	C07C 323/62		

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
48.		Brown, "Synthetic Inhibitors of Matrix Metalloproteinases"; <i>Matrix Metalloproteinases</i> , pp. 243-261 (Academic Press, San Diego, CA, Eds. Park, W.C., & Mecham, R.P., 1998)
49.		Dack, et al., "Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors," CA 131:44740 (1999)
50.		Denis, et al., "Matrix metalloproteinase inhibitors: Present achievements and future prospects," <i>Invest. New Drugs</i> , 15:175-185 (1997)
51.		Freije, et al., "Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas," <i>J. Biol. Chem.</i> , 269(24), pp. 16766-16773 (1994)
52.		Gearing, et al., "Processing of tumour necrosis factor- $\alpha$ precursor by metalloproteinases", <i>Nature</i> , 370:555-557 (1994)
53.		Gu, et al., "S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death," <i>Science</i> , 297, 1186-1190 (2002)
54.		Hughes, et al., "Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism <i>in situ</i> and <i>in vitro</i> ," <i>Biochem. J.</i> , 305, 799-804 (1995)
55.		Kenyon, et al., "A Model of Angiogenesis in the Mouse Cornea," <i>Investigative Ophthalmology &amp; Visual Science</i> , Vol. 37, No. 8:1625-32 (July 1996)
56.		Knight, et al., "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases," <i>FEBS Lett.</i> , 296(3):263-266 (1992)
57.		Kuzmic, et al., "High-throughput screening of enzyme inhibitor: simultaneous determination of tright-binding inhibition constants and enzyme concentration," <i>Anal. Biochem.</i> , 286, 45-50 (2000)
58.		Luckow, et al., "Insect Cell Expression Technology", <i>Protein Engineering: Principles and Practice</i> , pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
SEP 29 2003  
TECHNICAL CENTER 1600/2900

<b>FORM HDP-1449 (Based on Form PTO-1449)</b>  <b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)  Sheet 3 of 3	ATTORNEY DOCKET NO.	SERIAL NO.
	01136/1/US	10/600,041
	APPLICANT	
	Daniel P. Becker, et al.	
	FILING DATE	GROUP
June 25, 2003	1614	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
59.		Luckow, et al., "Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherihia coli," <i>J. Virol.</i> , 67(8):4566-4579 (1993)
60.		McClure, et al., "Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases," <i>CA</i> 131:125454 (1999) [CA Plus Accession No. 1999:468334]
61.		McGeehan, et al., "Regulation of tumour necrosis factor- $\alpha$ processing by a metalloproteinase inhibitor," <i>Nature</i> , 370:558-561 (1994)
62.		Mitchell, et al., "Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage," <i>J. Clin. Invest.</i> , 97(3):761-768 (1996)
63.		Rasmussen, et al., "Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat," <i>Pharmacol. Ther.</i> , 75(1):69-75 (1997)
64.		Reboul, et al., "The new collagenase, collagenease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes," <i>J. Clin. Invest.</i> , 97(9):2011-2019 (1996).
65.		Schwartz, et al., "Synthetic inhibitors of bacterial and mammalian interstitial collagenases," <i>Prog. in Med. Chem.</i> , 29:271-334 (1992).
66.		Tang, "ADAMTS: a novel family of extracellular matrix proteases," <i>Int'l J. Biochem. Cell Biol.</i> , 33, 33-44 (2001)
67.		Woessner, "The Matrix Metalloproteinase Family," <i>Matrix Metalloproteinases</i> , pp. 1-14 (Academic Press, San Diego, CA, Eds. Parks, W.C. & Mecham, R.P., 1998)

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.